Herein, we demonstrated that ALCAT1-mediated abnormal cardiolipin remodelling may contribute to HG-induced mitochondrial damage and podocyte injury by inhibiting the AMPK pathway, which suggests that ALCAT1 might be a therapeutic target for DKD. This evidence concerns the gene LCLAT1 and diabetic kidney disease.